Saltar al contenido principal
xMedica

NCT07915791ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and…

Fase 2279 participantes buscados10 centros2 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-11-04; recorded start 2026-10-29
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 336 other studies in this databaseCounted from the lead sponsor named in the record (GlaxoSmithKline)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding16/20

    Triple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 10 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 279 participants (target), run at 10 sites, across 2 countries.

How this score is built
  • Enrolment24/40

    279 participants (target)

  • Site count12/25

    10 sites

  • Country count7/15

    2 countries

  • Planned duration8/10

    Planned over about 40 months

  • Sponsor scale9/10

    GlaxoSmithKline has led 337 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.

Afecciones

  • Pulmonary Disease, Chronic Obstructive

Elegibilidad

Elegibilidad
SexoTodos
Edades40 Years – 80 Years
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent * Basal Metabolic Rate (BMI) \>= 16 kilogram per meter square (kg/m\^2) * Moderate to severe COPD with frequent exacerbations, defined as * a clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year prior to the screening visit; * a post-salbutamol FEV1/Forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post-salbutamol FEV1 greater than (\>) 30 percent (%) and \>= 80% predicted normal values calculated withGlobal Lung Function Initiative (GLI) - Global Race Neutral equations in line with the American Thoracic Society (ATS) recommendations at screening; * a well-documented history (e.g., medical record verification, including capturing of all prior biologic use) of at least 2 moderate or 1 severe exacerbations in the 12 months prior to screening despite the use of Inhaled Corticosteroids (ICS) containing maintenance COPD treatment; at least one qualifying exacerbation must have occurred while participant was on ICS plus long-acting muscarinic antagonist (LAMA) plus long-acting beta agonist (LABA); Moderate exacerbations must have been treated with systemic corticosteroids and/or antibiotics (subcutaneous \[SCS\]; Intramuscular \[IM\], Intravenous \[IV\], or oral); Severe exacerbations are those requiring hospitalization or observation \>24 hours in the emergency department /urgent care facility * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening. Former smokers are defined as those who have stopped all cigarette smoking for at least 6 months prior to the Screening Visit * An eosinophilic phenotype with elevated Blood eosinophil count (BEC) at screening * CAT total score ≥ 10, * Participants should be on standard of care COPD maintenance inhaler therapy, defined as ICS plus LAMA plus LABA either as multiple inhalers or a single combination inhaler for at least 6 months prior to the Screening Visit and on a stable dose for at least 3 months prior to the Screening Visit * Participants on adjunctive COPD therapies such as chronic macrolide antibiotics, Phosphodiesterase (PDE)4 or PDE3-4 inhibitors, or chronic oral corticosteroids (up to 15 mg prednisone equivalent per day) may participate, provided they have been on these medications for 6 months, and on a stable dose for at least 3 months immediately prior to the Screening Visit * A female participant is eligible to participate if she is not pregnant or breastfeeding * Is a Participant of non-childbearing potential (PONCBP) * Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of \<1%, at least 42 days prior to and during the study intervention period and for at least 60 weeks after the last dose of study intervention. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol Exclusion Criteria: * Participants with a current or prior physician diagnosis of asthma are excluded * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Participants with α1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases * COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening are excluded * Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure are excluded * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to the Screening Visit are excluded. Participants who are in the maintenance phase of a pulmonary rehabilitation program may participate * Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day are excluded. Non-continuous (i.e., 12 hours or less per day) oxygen is permitted up to 2 Liters per minute (L/min) at the time of the screening visit and for the duration of the study. Participants on long term oxygen therapy (LTOT) should be ambulatory and able to attend clinic visits * Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension is excluded * Chronic hypercapnia requiring Non-invasive Positive Pressure Ventilation (NIPPV) use (including Bilevel Positive Airway Pressure \[BiPAP\] or Continuous positive airway pressure \[CPAP\]) are excluded * Participants with unstable cardiac disease; myocardial infarction or stroke within 12 months prior to screening; or New York Heart Association Class III or IV heart failure * Participants with clinically significant abnormal Electrocardiogram (ECG) at screening which in the judgment of the Investigator, may affect participant safety or affect study endpoints * Participants with a history of lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected for cure with no evidence of recurrence or metastatic disease for 1-year * A known or suspected immunodeficiency that has led to opportunistic infections, recurrent invasive infections, or prolonged infections that suggest an underlying immunocompromised state by the judgement of the investigator. Positive HIV antibody test * Active Nontuberculous mycobacterial (NTM) lung infection on treatment or meeting ATS/ Infectious Diseases Society of America (IDSA) criteria for active lung infection * Active tuberculosis, untreated latent Tuberculosis (TB), invasive fungal lung infections or allergic bronchopulmonary aspergillosis needing treatment * Participants should not have an active, invasive fungal infection as assessed by the investigator and should not be on chronic antifungal therapy. Participants who have completed antifungal therapy more than 4 weeks prior to screening and have been deemed clinically cured are eligible * Vasculitis: Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment * Eosinophilic disease: Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA) (also known as Churg-Strauss Syndrome), or Eosinophilic Esophagitis * Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening, or infection detected at Screening * History of an unresolved clinically significant infection within 30 days prior to the screening visit * Immunodeficiency: A known immunodeficiency other than that explained by use of corticosteroids (e.g., HIV) * Other concurrent medical conditions: Participants with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Clinically significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study * A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report * Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B virus (HBV) DNA at screening or within 3 months prior to first dose of study intervention. HBV DNA will only be tested if a participant is core antibody positive * Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention * Alanine aminotransferase (ALT) \>2\*Upper Limit to Normal (ULN) * Total bilirubin \>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \>1.5xULN as long as direct bilirubin is \<=1.5\*ULN * Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice * Previous documented treatment failure or non-response to anti-IL-33 or anti - Thymic Stromal Lymphopoietin (TSLP) therapy * Short term oral corticosteroids: Participants who have received short term use of oral corticosteroids within 4 weeks of the Screening Visit * Use of immunosuppressive medication (e.g., methotrexate, mycophenolate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, maintenance systemic (oral) corticosteroids for an indication other than COPD) within 3 months prior to screening and up until the end of the study treatment period (i.e., Week 24-72 depending on whether the participant is scheduled to receive 2-6 doses of the study intervention) * Received any live attenuated vaccine within 30 days prior to screening or plans to receive such vaccines up until the end of the study * Ongoing treatment with cyclic doses of systemic antibiotics * Current enrollment or past participation in another investigational study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within the following time period prior to the screening visit of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). This also includes investigational formulations of a marketed product * Previously participated in any clinical study with biologic treatments for respiratory conditions (e.g., omalizumab, mepolizumab, dupilumab, reslizumab, benralizumab, tezepelumab or depemokimab) and received study intervention (including placebo) within 12 months prior to Screening * Receipt of any investigational non-biologic agent within 1 month or 5 half-lives prior to screening, whichever is longer and up until the end of the follow-up period * Experimental vaccines are not permitted within 30 days prior to randomization and up until the end of the follow-up period * Previous randomization in the present study * Known or suspected history of alcohol or drug abuse with 2 years prior to screening * History of severe allergic reaction, anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 2
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoTRIPLE (3)
Inscripción279 participantes buscados

Patrocinador y colaboradores

  • GlaxoSmithKline Patrocinador

Grupos e intervenciones

  • GSK3862995B co-administered with GSK5784283EXPERIMENTAL

    Participants will receive co-administration of GSK3862995B and GSK5784283 in addition to their standard of care (SoC) triple therapy for COPD.

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive a matching placebo in addition to their SoC triple therapy for COPD.

Intervenciones

  • Fármaco GSK3862995B

    Participants will receive GSK3862995B.

  • Fármaco GSK5784283

    Participants will receive GSK5784283.

  • Fármaco Placebo

    Participants will receive matching Placebo.

Variables de resultado

  1. Variable de resultado principal

    Annualized Rate of Moderate/severe Exacerbations in Former Smokers

    A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers.

    Plazo Up to 72 weeks

  2. Variable de resultado secundaria

    Number of Participants with Serious Adverse Events and Adverse Events in All Comers (Former and Current smokers) with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

    Plazo Up to 120 weeks

  3. Variable de resultado secundaria

    Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) in All Comers (Former and Current smokers) with Moderate to Severe COPD

    Plazo Up to 120 weeks

  4. Variable de resultado secundaria

    Time to First Exacerbation in Former Smokers with Moderate to Severe COPD

    Plazo Up to 72 weeks

  5. Variable de resultado secundaria

    Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in Former Smokers with Moderate to Severe COPD

    Plazo Baseline and Week 24

  6. Variable de resultado secundaria

    Change from Baseline in SGRQ-C total score at Week 24 in Former Smokers with Moderate and Severe COPD

    The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status).

    Plazo Baseline and Week 24

  7. Variable de resultado secundaria

    Change from baseline in the COPD Assessment Test (CAT) Score at Week 24 in Former Smokers with Moderate to Severe Smokers

    The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health.

    Plazo Baseline and Week 24

  8. Variable de resultado secundaria

    Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in Former Smokers with Moderate to Severe COPD

    The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness.

    Plazo Baseline and Week 24

  9. Variable de resultado secundaria

    Annualized rate of Moderate/Severe Exacerbations in all Comers (Former and Current smokers)

    A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers.

    Plazo Up to 72 weeks

  10. Variable de resultado secundaria

    Time to First Exacerbation in all Comers (Former and current Smokers) with Moderate to Severe COPD

    Plazo Up to 72 weeks

  11. Variable de resultado secundaria

    Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in all comers (Former and Current Smokers) with Moderate to Severe COPD

    Plazo Baseline and Week 24

  12. Variable de resultado secundaria

    Change from Baseline in SGRQ-C total score at Week 24 in all Comers (Former and Current Smokers) with Moderate and Severe COPD

    The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status).

    Plazo Baseline and Week 24

  13. Variable de resultado secundaria

    Change from baseline in the CAT Score at Week 24 all Comers (Former and Current Smokers) with Moderate to Severe Smokers

    The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health.

    Plazo Baseline and Week 24

  14. Variable de resultado secundaria

    Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in all comers (Former and current Smokers) with Moderate to Severe COPD

    The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness.

    Plazo Baseline and Week 24

  15. Variable de resultado secundaria

    Serum concentrations of GSK3862995B and GSK5784283 in all comers (former and current smokers) with moderate to severe COPD

    Plazo Week 2; pre-dose on Weeks 12, 24, 36, 48, 60; and Week 72

Fechas

Fechas
Fecha de inicio29 de octubre de 2026 (real)
Finalización principal7 de marzo de 2029 (estimada)
Finalización6 de febrero de 2030 (estimada)
Primera publicación4 de noviembre de 2026 (real)
Última actualización17 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

10 centros están en reclutamiento

United Kingdom

United Kingdom
CentroCiudadEstado o regiónEstado
GSK Investigational SiteBradfordEn reclutamiento
GSK Investigational SiteLondonEn reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
GSK Investigational SiteColumbiaMarylandEn reclutamiento
GSK Investigational SiteDerbyKansasEn reclutamiento
GSK Investigational SiteMiamiFloridaEn reclutamiento
GSK Investigational SiteNewport BeachCaliforniaEn reclutamiento
GSK Investigational SiteOklahoma CityOklahomaEn reclutamiento
GSK Investigational SitePhiladelphiaPennsylvaniaEn reclutamiento
GSK Investigational SiteRock HillSouth CarolinaEn reclutamiento
GSK Investigational SiteTomballTexasEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 17 de noviembre de 2026

    Estado modificado

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 17 de noviembre de 2026

    Reclutamiento abierto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. 17 de noviembre de 2026

    Fecha de finalización adelantada

    Primary completion advanced 9 days

    2029-03-162029-03-07

  4. 17 de noviembre de 2026

    Centro añadido

    10 sites added (10 total)

    010